[Beijing Fourth Intermediate People’s Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan BEIJING, September 28, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that ]
[Beijing Fourth Intermediate People’s Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan BEIJING, September 28, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that ]
[Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivate]
[Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivate]
[Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children BEIJING, China, September 23, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutica]
[Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children BEIJING, China, September 23, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutica]
[Sinovac Reports Unaudited Second Quarter 2020 Financial Results BUSINESS WIRE BEIJING--( Second Quarter and First Half of 2020 Financial Summary • Sales for the second quarter of 2020 were $52.3 million, a decrease of 18.3% from $64.0 million in the prior year period. • Sales for the six months ende]
[Sinovac Reports Unaudited Second Quarter 2020 Financial Results BUSINESS WIRE BEIJING--( Second Quarter and First Half of 2020 Financial Summary • Sales for the second quarter of 2020 were $52.3 million, a decrease of 18.3% from $64.0 million in the prior year period. • Sales for the six months ende]
[Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation BEIJING, China – August 25, 2020 -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has signed two agreements in Hainan, Ch]
[Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation BEIJING, China – August 25, 2020 -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has signed two agreements in Hainan, Ch]
